Cobimetinib Clinical Trials
8 recruitingDrug
Phase 26Phase 31Early Phase 11Phase 11
Showing 1–8 of 8 trials
Recruiting
Phase 1
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
Metastatic Endometrial CarcinomaStage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8+8 more
National Cancer Institute (NCI)42 enrolled6 locationsNCT05691504
Recruiting
Phase 2
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
Genentech, Inc.99 enrolled38 locationsNCT04302025
Recruiting
Phase 2
Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma
Advanced or Metastatic Melanoma
Hanmi Pharmaceutical Company Limited45 enrolled10 locationsNCT07449754
Recruiting
Early Phase 1
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8+5 more
OHSU Knight Cancer Institute90 enrolled1 locationNCT04005690
Recruiting
Phase 2
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
Thyroid Gland Follicular CarcinomaThyroid Gland Oncocytic CarcinomaThyroid Gland Papillary Carcinoma
City of Hope Medical Center21 enrolled1 locationNCT06440850
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
MelanomaOvarian NeoplasmsColorectal Neoplasms+3 more
Cancer Research UK30 enrolled16 locationsNCT05768178
Recruiting
Phase 2
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
Langerhan's Cell HistiocytosisJuvenile XanthogranulomaErdheim-Chester Disease+4 more
Carl Allen90 enrolled12 locationsNCT04079179
Recruiting
Phase 2
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Advanced CancerSolid TumorHaematological Malignancy
Helsinki University Central Hospital250 enrolled5 locationsNCT05159245